Otsuka (OTCMKTS:OTSKY) Updates FY 2026 Earnings Guidance

Otsuka (OTCMKTS:OTSKY) updated its FY 2026 earnings guidance on Friday. The company provided earnings per share (EPS) guidance of 2.119-2.119 for the period, compared to the consensus EPS estimate of 1.980. The company issued revenue guidance of $17.1 billion-$17.1 billion, compared to the consensus revenue estimate of $16.7 billion.

Otsuka Trading Up 2.2%

OTCMKTS:OTSKY opened at $35.83 on Friday. The company has a quick ratio of 1.67, a current ratio of 2.17 and a debt-to-equity ratio of 0.05. The business’s 50 day moving average is $34.19 and its two-hundred day moving average is $33.51. Otsuka has a 52 week low of $23.67 and a 52 week high of $37.52. The company has a market cap of $38.49 billion and a PE ratio of 15.12.

Otsuka (OTCMKTS:OTSKY) last issued its quarterly earnings results on Tuesday, April 28th. The company reported $0.59 earnings per share for the quarter, beating analysts’ consensus estimates of $0.43 by $0.16. The business had revenue of $3.96 billion during the quarter, compared to the consensus estimate of $3.78 billion. Otsuka had a return on equity of 12.33% and a net margin of 15.01%. On average, analysts predict that Otsuka will post 1.96 EPS for the current year.

Otsuka Company Profile

Otsuka Pharmaceutical Co, Ltd., trading in the U.S. under the ticker OTCMKTS:OTSKY, is a global healthcare company headquartered in Tokyo, Japan. The firm’s core activities span the development, manufacturing and marketing of prescription pharmaceuticals, consumer healthcare products and nutraceuticals. Otsuka focuses its research on areas such as neuroscience, cardiovascular and renal therapies, and oncology, aiming to bring innovative treatments to patients worldwide.

Founded in 1964 by Busaburo Otsuka as a subsidiary of the Otsuka Group, the company has grown into a diversified healthcare enterprise over more than five decades.